Trial Profile
Phase III trial for combination of Durvalumab and Gefitinib as first line treatment in EGFR mutation NSCLC
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 04 Jun 2015 New trial record